From support to recovery: the evolving role of LVAD in reversing heart failure

Guardado en:
Detalles Bibliográficos
Publicado en:Journal of Cardiothoracic Surgery vol. 20 (2025), p. 1-10
Autor principal: Sun, Bingqi
Otros Autores: Liu, Zhigang
Publicado:
Springer Nature B.V.
Materias:
Acceso en línea:Citation/Abstract
Full Text
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

MARC

LEADER 00000nab a2200000uu 4500
001 3247162016
003 UK-CbPIL
022 |a 1749-8090 
024 7 |a 10.1186/s13019-025-03560-1  |2 doi 
035 |a 3247162016 
045 2 |b d20250101  |b d20251231 
084 |a 113327  |2 nlm 
100 1 |a Sun, Bingqi 
245 1 |a From support to recovery: the evolving role of LVAD in reversing heart failure 
260 |b Springer Nature B.V.  |c 2025 
513 |a Journal Article 
520 3 |a In recent years, the use of Left Ventricular Assist Devices (LVAD) in the treatment of heart failure has been increasingly widespread. Not only do they provide circulatory support for patients, but the reverse biological changes in myocardial tissue induced by LVAD have led to the recovery of heart function in some patients, allowing for the removal of the device—which termed bridge to recovery (BTR). Despite promising prospective studies reporting LVAD explantation rates exceeding 48–60% in BTR-focused cohorts, real-world registries (e.g., INTERMACS) demonstrate explantation rates below 5%, underscoring critical gaps in patient selection, standardized assessment protocols, and integration of optimized pharmacological and mechanical unloading strategies. This review synthesizes contemporary clinical and molecular insights into LVAD-mediated myocardial recovery. Clinically, key determinants of successful BTR include stringent hemodynamic and echocardiographic criteria for explantation (e.g., LVEF > 45%, PCWP ≤ 15 mmHg), and aggressive guideline-directed medical therapy (GDMT), particularly neurohormonal blockade. Mechanistically, LVAD unloading promotes reverse remodeling through metabolic reprogramming (e.g., enhanced pyruvate-lactate axis activity), restoration of calcium homeostasis, extracellular matrix modulation, and immune-mediated pathways. However, challenges persist, including the lack of predictive biomarkers, suboptimal GDMT adherence, and unresolved debates regarding concomitant cardiac procedures. Emerging evidence highlights the potential of novel pharmacotherapies (e.g., SGLT2 inhibitors, vericiguat) and individualized pump-speed algorithms to augment recovery. Pediatric populations exhibit unique recovery dynamics, with myocarditis and smaller body surface area correlating with higher explantation success. Partial cardiac recovery, observed in over 30% of LVAD recipients, warrants tailored therapeutic strategies to transition to full recovery. Future directions demand multicenter registries integrating molecular profiling with clinical outcomes, standardized BTR protocols, and exploration of adjuvant therapies. By redefining BTR as an achievable goal rather than a rare exception, this paradigm shift could transform advanced heart failure management, offering patients liberation from lifelong device dependency. 
653 |a Intubation 
653 |a Infections 
653 |a Pyruvic acid 
653 |a Hemodynamics 
653 |a Chemical synthesis 
653 |a Ejection fraction 
653 |a Calcium (extracellular) 
653 |a Heart diseases 
653 |a Heart failure 
653 |a Ventricular assist devices 
653 |a Heart function 
653 |a Recovery 
653 |a Homeostasis 
653 |a Extracellular matrix 
653 |a Patients 
653 |a Thrombosis 
653 |a Medical prognosis 
653 |a Failure 
653 |a Congestive heart failure 
653 |a Cardiac catheterization 
653 |a Ostomy 
653 |a Mechanical unloading 
653 |a Biomarkers 
653 |a Myocarditis 
653 |a Enzymes 
653 |a Systematic review 
653 |a Cardiac function 
653 |a Pediatrics 
653 |a Calcium homeostasis 
653 |a Weaning 
700 1 |a Liu, Zhigang 
773 0 |t Journal of Cardiothoracic Surgery  |g vol. 20 (2025), p. 1-10 
786 0 |d ProQuest  |t Health & Medical Collection 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3247162016/abstract/embedded/75I98GEZK8WCJMPQ?source=fedsrch 
856 4 0 |3 Full Text  |u https://www.proquest.com/docview/3247162016/fulltext/embedded/75I98GEZK8WCJMPQ?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3247162016/fulltextPDF/embedded/75I98GEZK8WCJMPQ?source=fedsrch